Overall, modulation of the STING pathway influences HCC progression; thus, STING agonist treatment could be used in combination with other immunomodulatory therapies or standard therapies, such as PD1 inhibitors, against HCC (Thomsen et al. 2020). The gene discussed is STING1; the disease is hepatocellular carcinoma.